Roche NimbleGen gets new CEO; Dyax raises $52M; Keryx R&D expenses triple;

 @FierceBiotech: Small biotech offers its investors an easy way out. Article | Follow @FierceBiotech

 @JohnCFierce: HIV vax investigators are using social media to recruit for clinical trials. This is a hot trend in trial recruitment. | Follow @JohnCFierce

> Madison, WI-based Roche NimbleGen, which provides microarray tools for genetic discovery and analysis, named Frank Pitzer as its new CEO. NimbleGen release

> Dyax is raising close to $52 million from a stock sale to help finance the production and distribution of Kalbitor, a drug designed to treat hereditary angioedema. Some of the money will also go toward new research and preclinical activities. Dyax release

> Keryx Biopharmaceuticals says its losses grew in the fourth quarter as R&D expenses tripled. Story

> Venn Life Sciences has raised $3 million in a new funding round. Venn Life is a clinical trial services provider. Venn release

> Steve Lundy has joined AspenBio as CEO and will become a member of the board of directors. Daryl Faulkner, who served as interim CEO in 2009, will relinquish that role but will continue as executive chairman. AspenBio release

> Arena Pharmaceuticals has launched an early-stage study of an experimental narcolepsy and cataplexy therapy. Story

> MDRNA acquired DNA technology-related patents from Valeant Pharmaceuticals for an undisclosed amount. Report

And Finally... Researchers at Umeå University can now show that cells that grow forever get this capacity through gradual changes in the expression of genes that govern the repair of DNA damage and regulate growth and cell death. Report

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.